In tumor patients, sMICA/sMICB reduces the expression of NKG2D on the surfaces of NK cells and weakens the function of NK cells, allowing tumor cells to evade NKG2D-mediated immune surveillance [13]. The gene discussed is KLRK1; the disease is neoplasm.